A groundbreaking clinical trial is underway, seeking individuals diagnosed with Coeliac Disease throughout the Mackay and Whitsundays.
Spearheaded by Mackay's Coral Sea Clinical Research Institute (CSCRI), this early phase trial is dedicated to investigating the potential of ZED1227 - a revolutionary small molecule tissue transglutaminase (TG2) inhibitor as a promising treatment for Coeliac Disease.
“Patients with celiac disease urgently need appropriate therapeutic options to manage the significant negative impacts of the disease on health and daily quality of life,” said Roland Greinwald, Ph.D., Managing Director Medicine & Pharmaceutics at Dr. Falk Pharma, the company behind this latest advance in progressing a new therapy for Coeliac Disease.
Coeliac disease is an autoimmune-mediated chronic inflammatory condition of the small intestine affecting about 1.4% of the Australian population. The autoimmune disease is triggered by dietary gluten and consumption of foods containing wheat, barley, or rye leads to destruction of the small intestinal mucosa in genetically susceptible individuals, ZED1227 selectively binds to the active state of TG2, and has been designed for the treatment of coeliac disease.
“This is another very important study involving a potential treatment for Coeliac Disease, particularly as the only available treatment for Coeliac Disease remains a gluten free diet,” said Dr. James Daveson, a gastroenterologist and principal investigator for the study at CSCRI.
“CSCRI are particularly excited about how successful we have been in attracting companies to undertake their global studies for Coeliac Disease in the Mackay-Isaac-Whitsunday region given it is the only regional site involved outside of South-East Queensland.”
The study at the CSCRI requires people diagnosed with biopsy proven Coeliac Disease who are experiencing symptoms despite maintaining a gluten free diet for at least 12 months. Participants will need to come in to CSCRI for their visits.
If you are interested in being involved, please contact the research team on 1800 69 27 27 (1800 MY CSCRI), email at admin@coralseaclinical.com or visit the website at www.coralseaclinical.com
Dr James Daveson - Gastroenterologist and Director at Coral Sea Clinical Research Institute
Publishers Indemnity. Any individual or entity that places advertising, supplies copy material, or submits editorial content to Core Life Publishing agrees and undertakes to ensure that all such material:- Does not infringe upon any copyright, trademark, or other intellectual property rights;- Is free from any content that could be considered defamatory, libelous, or slanderous;- Does not infringe upon any rights related to privacy or breach of confidence;- Contains no obscene, indecent, or otherwise unlawful material;- Complies fully with the Trade Practices Act and all other applicable laws, regulations, or statutes.Furthermore, by submitting or placing such material, these individuals or entities agree to indemnify and hold harmless the publisher, Core Publishing and Events Pty Ltd, and/or its agents from and against any and all investigations, claims, demands, liabilities, damages, costs, or judgments arising out of or in connection with the material provided. All material is believed to be accurate at the time of printing and remains the copyright of Core Publishing and Events Pty Ltd.
© 2024 Mackay and Whitsunday Life Pty Ltd.
